natgillin/translations-raw huggingface dataset:
Based on the experience with healthy subjects exposed to oral netupitant 600 mg in combination with palonosetron 1.50 mg the potential acute symptoms of overdose are headache, dizziness, constipation, anxiety, palpitations, euphoric mood and pain in the legs. 
Na temelju iskustva sa zdravim ispitanicima koji su bili izloženi peroralnom netupitantu u dozi od 600 mg u kombinaciji s palonozetronom od 1,50 mg, mogući akutni simptomi predoziranja su glavobolja, omaglica, konstipacija, anksioznost, palpitacije, euforično raspoloženje i bolovi u nogama.
Serotonergic medicinal products (e.g. SSRIs and SNRIs) 
Serotoninergički lijekovi (npr. SSRI i SNRI)
• The other ingredients are microcrystalline cellulose (E460), sucrose lauric acid esters, povidone K-30, croscarmellose sodium, colloidal hydrated silica, sodium stearyl fumarate, magnesium stearate, glycerol monocaprylocaproate (type I), glycerol, polyglyceryl oleate, purified water, butylhydroxyanisole (E320), gelatin, sorbitol, 1,4 sorbitan, titanium dioxide (E171), shellac glaze (partially esterified), yellow, red and black iron oxide (E172), propylene glycol (E1520). 
• Drugi sastojci su mikrokristalična celuloza (E460), saharozni esteri lauratne kiseline, povidon K-30, umrežena karmelozanatrij, koloidni hidratizirani silicijev dioksid, natrijev stearilfumarat, magnezijev stearat, glicerolmonokaprilokaprat (vrsta I), glicerol, poligliceriloleat, pročišćena voda, butilhidroksianizol (E320), želatina, sorbitol, 1,4 sorbitan, titanijev dioksid (E171), šelakova glazura (djelomično esterificirana), žuti, crveni i crni željezov oksid (E172), propilenglikol (E1520).
Netupitant/palonosetron capsules, when given with a single oral dose of 60 μg ethinylestradiol and 300 μg levonorgestrel had no significant effect on the AUC of ethinylestradiol and increased the AUC of levonorgestrel by 1.4-fold; clinical effects on the efficacy of hormonal contraception are unlikely. 
Kad su se netupitant/palonozetron kapsule davale s jednom peroralnom dozom od 60 μg etinilestradiola i 300 μg levonorgestrela, nisu imale značajan učinak na AUC etinilestradiola i povećale su AUC levonorgestrela za 1,4 puta; klinički učinci na djelotvornost hormonskih kontraceptiva nisu vjerojatni.
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before taking Akynzeo. 
Ako se nešto od gore navedenog odnosi na Vas (ili niste sigurni), obratite se liječniku, ljekarniku ili medicinskoj sestri prije nego što uzmete Akynzeo.
moxifloxacin, haloperidol, chlorpromazine, quetiapine, thioridazine or domperidone 
kinidin, moksifloksacin, haloperidol, klorpromazin, kvetiapin, tioridazin ili domperidon
• palonosetron. 
• palonozetron.
Caution should be exercised in patients with severe hepatic impairment since limited data are available in these patients. 
Potreban je oprez u bolesnika s teškim oštećenjem funkcije jetre jer su podaci u tih bolesnika ograničeni.
• coating of the tongue, difficulty swallowing, dry mouth, belching, abnormal taste after medicine intake 
• obložen jezik, otežano gutanje, suha usta, podrigivanje, neprirodan okus nakon uzimanja lijeka
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. 
Ispitivanja na životinjama ne ukazuju na izravne ili neizravne štetne učinke na trudnoću, razvoj embrija/fetusa, parturiciju ili postnatalni razvoj.
However, since netupitant/palonosetron capsules contains a 5-HT3 receptor antagonist, caution should be exercised in concomitant use with medicinal products that increase the QT interval or in patients who have or are likely to develop prolongation of the QT interval. 
Međutim, budući da netupitant/palonozetron kapsule sadrže antagonist receptora 5-HT3, potreban je oprez kad se istovremeno primjenjuju lijekovi koji produljuju QT interval ili u bolesnika koji imaju ili u kojih bi se moglo razviti produljenje QT intervala.
Serotonin then activates 5-HT3 receptors located on vagal afferents to initiate the vomiting reflex. 
Serotonin zatim aktivira receptore 5HT3 smještene na vagusnim aferentnim vlaknima, čime se pobuđuje refleks povraćanja.
Titanium dioxide (E171) 
1,4 sorbitan titanijev dioksid (E171)
• medicines that might cause abnormal heartbeat such as amiodarone, nicardipine, quinidine, 
• lijekove koji mogu prouzročiti nepravilne srčane otkucaje kao što su amiodaron, nikardipin,
Three metabolites have been detected in human plasma at netupitant oral doses of 30 mg and higher (the desmethyl derivative, M1; the N-oxide derivative, M2; the OH-methyl derivative, M3). 
Kod peroralnih doza netupitanta od 30 mg i više, u ljudskoj plazmi otkrivena su tri metabolita (dezmetil derivat, M1; N-oksid derivat, M2; OH-metil derivat, M3).
Co-administration of a single dose of 300 mg netupitant with a dexamethasone regimen (20 mg on Day 1, followed by 8 mg twice daily from Day 2 to Day 4) significantly increased the exposure to dexamethasone in a time and dose dependent manner. 
Istovremena primjena jedne doze netupitanta od 300 mg s režimom deksametazona (20 mg 1. dana, a zatim 8 mg dvaput na dan od 2. do 4. dana) značajno je povećala izloženost deksametazonu na način ovisan o vremenu i dozi.
The proportion of patients with Overall no impact on daily life was 6.3% higher (p value =0.005) in the Akynzeo group (78.5%) than in the palonosetron group (72.1%). 
Udio bolesnika bez sveukupnog utjecaja na svakodnevni život bio je 6,3% veći (p-vrijednost = 0,005) u skupini koja je primala Akynzeo (78,5%) nego u skupini koja je primala palonozetron (72,1%).
Human plasma protein binding of netupitant and its two major metabolites M1 and M3 is > 99% at concentrations ranging from 10 to 1500 ng/mL. 
Vezanje netupitanta te njegovih dvaju glavnih metabolita M1 i M3 na proteine u ljudskoj plazmi iznosi > 99% pri koncentracijama u rasponu od 10 do 1500 ng/ml.
No dosage adjustment is necessary for patients with mild or moderate hepatic impairment (ChildPugh score 5-8). 
Nije potrebna prilagodba doze u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre (Child Pugh rezultat 5-8).
Degeneration of seminiferous epithelium was associated with palonosetron following a one month oral repeat dose toxicity study in rats. 
Degeneracija sjemenskog epitela bila je povezana s palonozetronom nakon mjesec dana ispitivanja toksičnosti ponovljenih peroralnih doze u štakora.
Hepatic impairment does not significantly affect total body clearance of palonosetron compared to the healthy subjects. 
Oštećenje jetrene funkcije ne utječe značajno na ukupni tjelesni klirens palonozetrona u usporedbi sa zdravim ispitanicima.
The hard capsules are opaque with a white body and a caramel cap with ‘HE1' printed on the body. 
Tvrde kapsule su neprozirne s bijelim tijelom i kapicom boje karamele, s oznakom „HE1“ otisnutom na tijelu.
• decreased blood flow to the heart muscle (myocardial ischemia) 
• smanjeni dotok krvi u srčani mišić (ishemija miokarda)
Chemotherapeutic substances produce nausea and vomiting by stimulating the release of serotonin from the enterochromaffin cells of the small intestine. 
Kemoterapijske tvari uzrokuju mučninu i povraćanje stimulacijom otpuštanja serotonina iz enterokromafinih stanica tankog crijeva.
No relevant changes of netupitant and palonosetron pharmacokinetics were observed. 
Nisu opažene značajne promjene farmakokinetike netupitanta i palonozetrona.
There are no data about the use of netupitant in pregnant women. 
Nema podataka o primjeni netupitanta u trudnica.
Netupitant No effect on fertility has been observed in animal studies. 
U ispitivanjima na životinjama nije opažen učinak na plodnost.
Netupitant/palonosetron capsules are contraindicated during pregnancy (see section 4.3). 
Netupitant/palonozetron kapsule kontraindicirane su tijekom trudnoće (vidjeti dio 4.3).
• you have a blockage in your gut, or you have had constipation in the past • you or one of your close relatives has ever had a heart problem called ‘QT interval prolongation' 
• Vi ili netko od Vama bliskih rođaka imali ste tegobe sa srcem pod nazivom „produljenje QT
Acute phase: 0 to 24 hours after anthracycline and cyclophosphamide regimen Delayed phase: 25 to 120 hours after anthracycline and cyclophosphamide regimen Overall: 0 to 120 hours after anthracycline and cyclophosphamide regimen 
Akutna faza: od 0 do 24 sata nakon protokola s antraciklinom i ciklofosfamidom Odgođena faza: od 25 do 120 sati nakon protokola s antraciklinom i ciklofosfamidom Cijela faza: od 0 do 120 sati nakon protokola s antraciklinom i ciklofosfamidom
Multiple-cycle safety study in patients receiving either Highly Emetogenic Chemotherapy or Moderately Emetogenic Chemotherapy 
Ispitivanje sigurnosti primjene u više ciklusa u bolesnika koji su primali visoko emetogenu kemoterapiju ili umjereno emetogenu kemoterapiju
In single dose oral studies, netupitant was measurable in plasma between 15 minutes and 3 hours after dosing. 
U ispitivanjima s jednom peroralnom dozom, netupitant je bio mjerljiv u plazmi između 15 minuta i 3 sata nakon primljene doze.
Caution is recommended when netupitant is combined with an oral substrate of this enzyme (e.g.zidovudine, valproic acid, morphine). 
Preporučuje se oprez kada se netupitant kombinira s peroralnim supstratom ovoga enzima (npr. zidovudinom, valproatnom kiselinom, morfinom).
Therefore, patients with known hypersensitivity to peanut or soya should be monitored closely for signs of an allergic reaction (see section 4.8). 
Stoga bolesnike s poznatom preosjetljivošću na kikiriki ili soju treba pomno nadzirati na znakove alergijske reakcije (vidjeti dio 4.8).
Rare 
Rijetke
• high levels of certain enzymes, including blood alkaline phosphatase and liver transaminases 
• visoke razine nekih enzima, uključujući alkalnu fosfatazu i jetrene transaminaze (prema pretragama krvi)
Therefore, patients with known hypersensitivity to peanut or soya should be monitored closely for signs of an allergic reaction. 
Stoga bolesnike s poznatom preosjetljivošću na kikiriki ili soju treba pomno nadzirati na znakove alergijske reakcije.
Effects in non-clinical studies based on safety pharmacology and single and repeated dose toxicity were observed only at exposures considered in excess of the maximum human exposure, indicating little relevance to clinical use. 
Učinci u nekliničkim ispitivanjima temljenim na sigurnosnoj farmakologiji i toksičnosti jedne i ponovljenih doza bili su opaženi samo kod izloženosti koje su se smatrale većima od maksimalne ljudske izloženosti, što ukazuje na mali značaj za kliničku primjenu.
In vitro data shows that netupitant inhibits UGT2B7, the magnitude of such an effect in the clinical setting is not established. 
In vitro podaci pokazuju da netupitant inhibira UGT2B7, no veličina takvog učinka nije ustanovljena u kliničkom okruženju.
Exposure to erythromycin and midazolam was increased approximately 1.3 and 2.4 fold, respectively, when each was co-administered with netupitant. 
Izloženost eritromicinu povećala se približno 1,3 puta, a midazolamu 2,4 puta kada je svaki od njih primijenjen istovremeno s netupitantom.
In a separate study, a total of 413 patients undergoing initial and repeat cycles of chemotherapy (including carboplatin, cisplatin, oxaliplatin, and doxorubicin regimens), were randomized to receive either Akynzeo (n=309) or aprepitant and palonosetron (n=104). 
U odvojenom ispitivanju, ukupno 413 bolesnika koji su primali početni i ponavljane cikluse kemoterapije (uključujući protokole s karboplatinom, cisplatinom, oksaliplatinom i doksorubicinom) bili su randomizirani i primali su ili Akynzeo (n = 309) ili aprepitant i palonozetron (n = 104).
Following administration of a single dose of Akynzeo, netupitant is eliminated from the body in a multi-exponential fashion, with an apparent mean elimination half-life of 88 hours in cancer patients. 
Nakon primjene jedne doze Akynzea u bolesnika s rakom, netupitant se eliminira iz tijela multieksponencijalno, s prividnim srednjim poluvijekom eliminacije od 88 sati.
What Akynzeo is and what it is used for 
Što je Akynzeo i za što se koristi
The primary efficacy endpoint was complete response (CR) rate (defined as no emetic episodes, no rescue medication) within 120 hours (overall phase) after the start of the highly emetogenic chemotherapy administration. 
Primarni ishod djelotvornosti bila je stopa potpunog odgovora (engl. complete response, CR) (definiran kao stanje bez emetičkih epizoda, bez simptomatske terapije) unutar 120 sati (cijela faza) nakon početka primjene visoko emetogene kemoterapije.
Each hard capsule contains 7 mg of sorbitol and 20 mg of sucrose. 
Jedna tvrda kapsula sadrži 7 mg sorbitola i 20 mg saharoze.
such as fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram or escitalopram 
(SSRI) - kao što su fluoksetin, paroksetin, sertralin, fluvoksamin, citalopram ili escitalopram
Reproductive studies in animals with netupitant do not indicate direct or indirect harmful effects with respect to fertility, parturition or postnatal development. 
Ispitivanja reprodukcije u životinja s netupitantom ne ukazuju na izravne ili neizravne štetne učinke na plodnost, parturiciju ili postnatalni razvoj.
Palonosetron: 
Palonozetron:
Pack size of one hard capsule or 4 x 1 hard capsules in perforated unit dose blisters. 
Veličina pakiranja od jedne tvrde kapsule ili 4 x 1 tvrde kapsule u perforiranom pakiranju s jediničnim dozama.
A pregnancy test should be performed on all pre-menopausal women prior to treatment. 
Prije liječenja, svim ženama koje nisu u menopauzi treba provesti test na trudnoću.
Hypokalaemia and hypomagnesaemia should be corrected prior to administration. 
Prije primjene potrebno je korigirati hipokalemiju i hipomagnezemiju.
Titanium dioxide (E171) Yellow iron oxide (E172) Red iron oxide (E172) 
želatina titanijev dioksid (E171) željezov oksid, žuti (E172) željezov oksid, crveni (E172)
As use in patients with severe hepatic impairment may be associated with increased exposure of netupitant, this medicinal product should be used with caution in these patients (see sections 4.4 and 
Budući da se primjena u bolesnika s teškim oštećenjem funkcije jetre može povezati s povećanom izloženosti netupitantu, u tih se bolesnika ovaj lijek mora primjenjivati s oprezom (vidjeti dijelove 4.4 i 5.2).
Common adverse reactions reported with netupitant/palonosetron capsules were headache (3.6%), constipation (3.0%) and fatigue (1.2%). 
Česte nuspojave zabilježene uz netupitant/palonozetron kapsule bile su glavobolja (3,6%), konstipacija (3,0%) i umor (1,2%).
• infection and inflammation in the bladder (cystitis) 
• infekcija i upala mokraćnog mjehura (cistitis)
There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and other serotonergic medicinal products (including SSRIs such as fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram or escitalopram and SNRIs such as venlafaxine or duloxetine) (see section 
Bilo je izvješća o serotoninskom sindromu nakon istovremene primjene antagonista 5-HT3 i drugih serotoninergičkih lijekova (uključujući SSRI-jeve kao što su fluoksetin, paroksetin, sertralin, fluvoksamin, citalopram ili escitalopram i SNRI-jeve kao što su venlafaksin ili duloksetin) (vidjeti dio
Cases of constipation with faecal impaction requiring hospitalisation have been reported in association with palonosetron 0.75 mg. 
Prijavljeni su slučajevi konstipacije s fekalnom impakcijom, koji su zahtijevali hospitalizaciju, povezani s primjenom palonozetrona u dozi od 0,75 mg.
Therefore, patients should be monitored for increased toxicity of chemotherapeutic agents that are substrates for CYP3A4, including irinotecan. 
Stoga je bolesnike potrebno nadzirati zbog povećane toksičnosti kemoterapijskih lijekova koji su supstrati za CYP3A4, uključujući irinotekan.
Delayed phase: 25 to 120 hours post-cisplatin treatment. 
Odgođena faza: od 25 do 120 sati poslije terapije cisplatinom.
As such, the oral dexamethasone dose should be reduced by approximately 50% when co-administered with netupitant/palonosetron capsules (see section 4.2). 
S obzirom na to, doza peroralnog deksametazona treba biti smanjena za otprilike 50% kada se primjenjuje istovremeno s netupitant/palonozetron kapsulama (vidjeti dio 4.2).
Opaque gelatin capsule of size “0” (length 21.7 mm) with white body and caramel cap with “HE1” printed on the body. 
Neprozirna želatinska kapsula veličine „0“ (duljina 21,7 mm), s bijelim tijelom i kapicom boje karamele te oznakom „HE1“ otisnutom na tijelu kapsule.
Following administration of a single oral 0.75 mg dose of [14C]-palonosetron to six healthy subjects, 85% to 93% of the total radioactivity was excreted in urine, and 5% to 8% was eliminated in faeces. 
Nakon primjene jedne peroralne doze od 0,75 mg [14C]-palonozetrona u šest zdravih ispitanika, 85% do 93% ukupne radioaktivnosti bilo je izlučeno mokraćom, a 5% do 8% eliminirano stolicom.
The primary efficacy endpoint was the CR rate in the delayed phase, 25-120 hours after the start of the chemotherapy administration. 
Primarni ishod djelotvornosti bila je stopa potpunog odgovora u odgođenoj fazi, 25 - 120 sati nakon početka primjene kemoterapije.
Very rare: may affect up to 1 in 10,000 people 
Vrlo rijetko: može se javiti u manje od 1 na 10 000 osoba
A total of 1450 patients (Akynzeo n=725; Palonosetron n=725) received study medication. 
Ispitivani lijek primilo je ukupno 1450 bolesnika (Akynzeo n = 725; palonozetron n = 725).
Netupitant AUC0-∞ and Cmax increased by 1.1 fold and 1.2 fold, respectively, after a high fat meal. 
AUC0-∞ i Cmax netupitanta povećali su se 1,1 puta odnosno 1,2 puta nakon obroka s visokim udjelom masti.
There have been reports of serotonin syndrome with the use of 5-HT3 antagonists either alone or in combination with other serotonergic medicinal products (including selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs). 
Bilo je izvješća o serotoninskom sindromu uz primjenu antagonista 5-HT3, bilo samih ili u kombinaciji s drugim serotoninergičkim lijekovima (uključujući selektivne inhibitore ponovne pohrane serotonina (SSRI) i inhibitore ponovne pohrane serotonina i noradrenalina (SNRI)).
Netupitant is not a substrate for P-gp. 
Netupitant nije supstrat P-gp-a.
This medicinal product can increase plasma concentrations of concomitantly administered medicinal products that are metabolised via CYP3A4. 
Ovaj lijek može povećati plazmatske koncentracije istovremeno primjenjivanih lijekova koji se metaboliziraju putem CYP3A4.
When this medicinal product is used concomitantly with medicinal products that induce CYP3A4 activity, netupitant plasma concentrations could be reduced and this may result in decreased efficacy. 
Kada se ovaj lijek uzima istovremeno s lijekovima koji induciraju aktivnost CYP3A4, koncentracije netupitanta u plazmi mogu biti snižene, a to može rezultirati smanjenom djelotvornošću.
Netupitant is a moderate inhibitor of CYP3A4 and can increase the exposure of chemotherapeutic agents that are substrates for CYP3A4 e.g. docetaxel (see section 4.5). 
Netupitant je umjereni inhibitor CYP3A4 i može povećati izloženost kemoterapijskim lijekovima koji su supstrati za CYP3A4, npr. docetaksel (vidjeti dio 4.5).
Chemotherapeutic agents that are substrates for CYP3A4 
Kemoterapijski lijekovi koji su supstrati za CYP3A4
Based on in vitro studies, palonosetron does not inhibit or induce cytochrome P450 isoenzyme at clinically relevant concentrations. 
Na temelju ispitivanja in vitro, palonozetron ne inhibira niti ne inducira izoenzime citokroma P450 u klinički važnim koncentracijama.
• The recommended dose is one capsule (each capsule contains 300 mg of netupitant and 0.5 mg of palonosetron). 
• Preporučena doza je jedna kapsula (jedna kapsula sadrži 300 mg netupitanta i 0,5 mg palonozetrona).
Overall: 0 to 120 hours post-cisplatin treatment. 
Cijela faza: od 0 do 120 sati poslije terapije cisplatinom.
Hard capsule. 
Tvrda kapsula
An ECG study was conducted in adult male and female healthy volunteers with oral netupitant either 200 or 600 mg administered in combination with oral palonosetron 0.5 or 1.5 mg, respectively. 
EKG ispitivanje provedeno je u zdravih odraslih dobrovoljaca, muškaraca i žena, s peroralnim netupitantom u dozi od 200 mg ili 600 mg primijenjeno u kombinaciji s peroralnim palonozetronom od 0,5 mg odnosno 1,5 mg.
In addition, eye swelling, dyspnoea and myalgia as adverse reactions have been reported with oral palonosetron but not observed during the development of this medicinal product. 
Osim toga, oticanje očiju, dispneja i mialgija zabilježene su kao nuspojave peroralnog palonozetrona, ali nisu opažene tijekom razvoja ovoga lijeka.
Exposure to netupitant (Cmax, AUC0-t and AUC0-∞) compared to matching healthy subjects was 11%, 28% and 19% higher in mild and 70%, 88% and 143% higher in moderate hepaticallyimpaired subjects, respectively. 
U usporedbi s podudarnim zdravim ispitanicima, izloženost netupitantu (Cmax, AUC0-t i AUC0-∞) bila je 11%, 28% i 19% viša u ispitanika s blagim oštećenjem funkcije jetre i 70%, 88% odnosno 143% viša u onih s umjerenim oštećenjem funkcije jetre.
This medicine contains 7 mg of sorbitol in each hard capsule. 
Ovaj lijek sadrži 7 mg sorbitola u jednoj tvrdoj kapsuli.
Palonosetron soft capsule 
Palonozetron meka kapsula
The European Medicines Agency has waived the obligation to submit the results of studies with Akynzeo in all subsets of the paediatric population in prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based and moderately emetogenic cancer chemotherapy (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove je izuzela obvezu podnošenja rezultata ispitivanja s lijekom Akynzeo u svim podskupinama pedijatrijske populacije u sprječavanju akutne i odgođene mučnine i povraćanja povezanih s visoko emetogenom kemoterapijom protiv raka temeljenom na cisplatinu, i umjereno emetogenom kemoterapijom protiv raka (za informacije o pedijatrijskoj primjeni vidjeti dio 4.2).
No dosage adjustment is necessary for elderly patients. 
U starijih bolesnika nije potrebna prilagodba doze.
Netupitant was shown to cross the blood brain barrier with a NK1 receptor occupancy of 92.5%, 86.5%, 85.0%, 78.0%, and 76.0% in striatum at 6, 24, 48, 72, and 96 hours, respectively, after administration of 300 mg netupitant. 
Pokazalo se da netupitant, nakon primjene u dozi od 300 mg, prolazi krvno-moždanu barijeru uz popunjenost receptora NK1 od 92,5%, 86,5%, 85,0%, 78,0% i 76,0% u strijatumu u 6., 24., 48., 72. odnosno 96. satu.
The study demonstrated no clinically important effects on ECG parameters: the largest point estimate of the placebo and baseline corrected QTc interval was 7.0 ms (one-sided upper 95% confidence limit 8.8 ms), observed 16 hours after the administration of supratherapeutic doses (600 mg netupitant and 1.5 mg palonosetron). 
Ispitivanje nije dokazalo klinički važne učinke na EKG parametre: najveća točkovna procjena QTc intervala korigiranog za placebo i početnu vrijednost bila je 7,0 ms (gornja granica jednostranog 95%-tnog intervala pouzdanosti 8,8 ms), opažena 16 sati nakon primjene supraterapijskih doza (600 mg netupitanta i 1,5 mg palonozetrona).
Table 3: Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase 
Tablica 3: Udio bolesnika koji su primali kemoterapiju cisplatinom u kojih je postignut odgovor, prema terapijskoj skupini i fazi
Very rare cases of anaphylaxis, anaphylactic/anaphylactoid reactions and shock have been reported from the post-marketing use of intravenous palonosetron. 
Vrlo rijetki slučajevi anafilaksije, anafilaktičnih/anafilaktoidnih reakcija i šoka zabilježeni su tijekom primjene intravenskog palonozetrona nakon stavljanja lijeka u promet.